Disease Diagnosis TRIZ Cases

FRα-specific antibodies replace invasive biopsies with biochemical assays, enabling non-invasive diagnosis of FRα-expressing cancers.

Detecting autoantibodies against MMP9 and EpCAM enables early liver cancer diagnosis beyond AFP limitations.

Folic acid functionalized copper sulfide nanoparticles detect ovarian circulating tumor cells via photoacoustic flow cytometry despite EpCAM down-regulation.

Whole blood chemiluminescence quantifies neutrophil superoxide production to evaluate cancer status.

Soluble LOX-1 protein measurement classifies neonatal hypoxic-ischemic encephalopathy severity within six hours of birth.

Diet-induced obesity in ferrets mimics human metabolic changes and viral spread, enabling accurate influenza treatment screening.

A polycation reagent enables precise latex agglutination measurement of thrombin-antithrombin complexes in blood samples.

Measuring urine clusterin levels identifies kidney transplant recipients at risk of interstitial fibrosis and tubular atrophy.

A T14 peptide biomarker detects cognitive decline through blood analysis of soluble and aggregated peptide concentrations.

Segmented reaction sequences in homogeneous immunoassays subtract background interference from total signal for accurate SDMA quantification.

Mid-regional pro-adrenomedullin levels predict chronic kidney disease progression independent of glomerular filtration rate.

Analyzing plasma kisspeptin and miR-324-3p levels resolves the contradiction between early detection timing and diagnostic accuracy.

A segmented diagnostic workflow applies rapid immunoassay or nucleic acid assays to identify positive fecal samples for targeted analysis.

Measuring chromogranin B and secretogranin II levels in body fluids diagnoses heart disease with high sensitivity.

A mass spectrometry assay measures beta-amyloid peptide concentrations in blood samples to determine patient recovery prognosis.

Segmenting the liver protein portfolio into specific biomarkers enables precise quantification of liver damage without invasive biopsy procedures.

Thermal shift assay detects protein melting temperature changes in patient samples to identify drug resistance biomarkers.

Adjusting procalcitonin cut-offs for immunocompromised patients improves antibiotic guidance reliability while reducing resistance risks.

DNA thioaptamer liposomes enable non-invasive MRI detection of early tau pathology.

An in vitro bioassay stimulates patient PBMCs to determine drug potency hierarchies and optimize immunosuppressant combinations.

Segments multiple tumor-associated antigens into a single diagnostic panel to resolve the contradiction between measurement precision and device complexity.

NT-proET-1 biomarker detection resolves low sensitivity in early heart disease diagnosis.

Multiplexed multispectral immunofluorescence imaging detects VISTA and other checkpoint proteins in tumor tissue samples.

Gold nanoparticle sensors detect volatile organic compounds in breath to diagnose tuberculosis without complex laboratory equipment.

Circulating CAML biomarkers track treatment response via size and number changes, replacing rare CTCs to improve early-stage detection reliability.

Analytes measured against age-specific reference ranges provide adjusted chronological age metrics.

Segmenting eleven specific p53 post-translational modifications via mass spectrometry resolves diagnostic ambiguity between dementia stages.

Measuring sCD14-ST concentration resolves low specificity of traditional markers, enabling accurate surgical site infection diagnosis.

A platelet-based diagnostic tool detects Alzheimer's disease through specific protein expression levels.

Segmenting diagnostic steps with HSP27 biomarkers resolves spirometry reliability issues for early disease detection.

Odd chain fatty acids modulate metabolic syndrome markers to reduce side effects from conventional drug therapies.

Specific binding agents quantify the sFlt-1:PlGF complex to enable early preeclampsia prediction before clinical symptoms appear.

A method matching test sample cell distributions to positive responder controls predicts clinical response likelihood.

Total free light chain serum measurement resolves inaccurate mortality prediction by establishing distinct reference ranges for pro-inflammatory cancers.

Targeting fetal membrane cell markers isolates cells from maternal blood, extending the diagnostic window beyond the standard twelve-week gestation limit.

A lateral flow test strip uses parallel antigen lanes to detect antibodies against Chagas disease, Leishmaniasis, and Heartworm.

Automated flow cytometry measures apoptosis in whole blood samples, resolving the trade-off between clinical correlation and incubation time.

Quantifying specific proteins in fecal droppings resolves invasive diagnostic trade-offs by correlating molecular markers with gut damage.

Antibodies detect MICA and MICB proteins in formalin-fixed paraffin-embedded tissue samples, resolving epitope destruction issues.

Blood lipid metabolite profiling detects non-alcoholic steatohepatitis through specific molecular signatures.

Deuterium-labeled glucose analysis quantifies fractional gluconeogenesis to estimate patient body energy state.

A biomarker panel detects host immune responses to distinguish active tuberculosis from latent infection.

Measuring troponin T, NT-proBNP, and GDF-15 concentrations in patient samples to identify left ventricular hypertrophy status.

A chimeric polypeptide uses a light-induced oligomerization domain to trigger protein aggregation upon blue light stimulation.

Monoclonal antibodies targeting galactose-deficient IgA1 enable non-invasive liquid biopsy diagnosis of IgA nephropathy, avoiding renal biopsy risks.

Detecting integrin beta subunits in blood samples provides a specific diagnostic method for venous thromboembolism.

Protein misfolding cyclic amplification overcomes low sensitivity in 4R tauopathies by using isoform-matched substrates to amplify misfolded tau aggregates.

Detecting VHL gene loss of function in tumor cells identifies patients responsive to PD-1 and PD-L1 targeting therapies.